Sakan Hirokazu, Nakatani Kimihiko, Asai Osamu, Imura Akihiro, Tanaka Tomohiro, Yoshimoto Shuhei, Iwamoto Noriyuki, Kurumatani Norio, Iwano Masayuki, Nabeshima Yo-Ichi, Konishi Noboru, Saito Yoshihiko
First Department of Internal Medicine, Nara Medical University, Kashihara, Nara, Japan.
First Department of Internal Medicine, Nara Medical University, Kashihara, Nara, Japan ; Department of Pathology, Nara Medical University, Kashihara, Nara, Japan.
PLoS One. 2014 Jan 23;9(1):e86301. doi: 10.1371/journal.pone.0086301. eCollection 2014.
Renal α-Klotho (α-KL) plays a fundamental role as a co-receptor for fibroblast growth factor 23 (FGF23), a phosphaturic hormone and regulator of 1,25(OH)2 vitamin D3 (1,25VitD3). Disruption of FGF23-α-KL signaling is thought to be an early hallmark of chronic kidney disease (CKD) involving reduced renal α-KL expression and a reciprocal rise in serum FGF23. It remains unclear, however, whether the rise in FGF23 is related to the loss of renal α-KL. We evaluated α-KL expression in renal biopsy samples and measured levels of several parameters of mineral metabolism, as well as soluble α-KL (sKL), in serum and urinary samples from CKD patients (n = 236). We found that although renal α-KL levels were significantly reduced and serum FGF23 levels were significantly elevated in early and intermediate CKD, serum phosphate levels remained within the normal range. Multiple regression analysis showed that the increases in FGF23 were significantly associated with reduced renal function and elevated serum phosphate, but were not associated with loss of renal α-KL. Moreover, despite falling renal α-KL levels, the increase in FGF23 enhanced urinary fractional excretion of phosphate and reduced serum 1,25VitD3 levels in early and intermediate CKD, though not in advanced CKD. Serum sKL levels also fell significantly over the course of CKD, and renal α-KL was a significant independent determinant of sKL. These results demonstrate that FGF23 levels rise to compensate for renal failure-related phosphate retention in early and intermediate CKD. This enables FGF23-α-KL signaling and a neutral phosphate balance to be maintained despite the reduction in α-KL. In advanced CKD, however, renal α-KL declines further. This disrupts FGF23 signaling, and serum phosphate levels significantly increase, stimulating greater FGF23 secretion. Our results also suggest the serum sKL concentration may be a useful marker of renal α-KL expression levels.
肾脏α-klotho(α-KL)作为成纤维细胞生长因子23(FGF23)的共受体发挥着重要作用,FGF23是一种排磷激素,也是1,25(OH)2维生素D3(1,25维生素D3)的调节剂。FGF23-α-KL信号通路的破坏被认为是慢性肾脏病(CKD)的早期标志,这涉及肾脏α-KL表达降低以及血清FGF23相应升高。然而,FGF23升高是否与肾脏α-KL缺失有关仍不清楚。我们评估了CKD患者(n = 236)肾活检样本中的α-KL表达,并测量了血清和尿液样本中矿物质代谢的几个参数以及可溶性α-KL(sKL)水平。我们发现,尽管在CKD早期和中期肾脏α-KL水平显著降低,血清FGF23水平显著升高,但血清磷酸盐水平仍在正常范围内。多元回归分析表明,FGF23升高与肾功能降低和血清磷酸盐升高显著相关,但与肾脏α-KL缺失无关。此外,尽管肾脏α-KL水平下降,但在CKD早期和中期,FGF23升高增强了尿磷排泄分数并降低了血清1,25维生素D3水平,而在晚期CKD中则不然。血清sKL水平在CKD病程中也显著下降,并且肾脏α-KL是sKL的重要独立决定因素。这些结果表明,在CKD早期和中期,FGF23水平升高以补偿与肾衰竭相关的磷潴留。这使得尽管α-KL减少,但仍能维持FGF23-α-KL信号通路和中性磷平衡。然而,在晚期CKD中,肾脏α-KL进一步下降。这破坏了FGF23信号通路,血清磷酸盐水平显著升高,刺激更多FGF23分泌。我们的结果还表明,血清sKL浓度可能是肾脏α-KL表达水平的有用标志物。